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Abstract
Background: Anemia continues to be a major public health problem among children in many regions of the
world, and it is still not clear which strategy to treat it is most effective.
Objective: To evaluate the efficacy and children’s acceptance of several recognized strategies to treat anemia.
Methods: Non-breastfed children (n = 577), 6 to 43 mo of age, were screened for the trial; 267 were anemic
(hemoglobin < 11.7 g/dL), and 266 of those were randomized into 1 of 5 treatments to received daily either: an
iron supplement (IS), an iron+folic acid supplement (IFS), a multiple micronutrient supplement (MMS), a
micronutrient-fortified complementary food as porridge powder (FCF), or zinc+iron+ascorbic acid fortified water
(FW). The iron content of each daily dose was 20, 12.5, 10, 10 and 6.7 mg respectively. Hemoglobin (Hb), ferritin,
total iron, weight and height were measured at baseline and after 4 months of treatment. Morbidity, treatment
acceptability and adherence were recorded during the intervention.
Results: All treatments significantly increased Hb and total iron concentration; ferritin did not change significantly.
Groups MMS, IS and IFS increased Hb (g/dL) [1.50 (95%CI: 1.17, 1.83), 1.48 [(1.18, 1.78) and 1.57 (1.26, 1.88),
respectively] and total iron ((μg/dL) [0.15 (0.01, 0.29), 0.19 (0.06, 0.31) and 0.12(-0.01, 0.25), respectively] significantly
more than FCF [0.92 (0.64, 1.20)] but not to FW group [0.14 (0.04, 0.24)]. The prevalence of anemia was reduced to
a greater extent in the MMS and IFS groups (72% and 69%, respectively) than in the FCF group (45%) (p < 0.05).
There were no significant differences in anthropometry or in the number of episodes of diarrhea and respiratory
infections among treatment groups. The supplements MMS and IS were less acceptable to children, than IFS, FCF
and FW.
Conclusion: The three supplements IS, ISF and MMS increased Hb more than the FCF; the supplements that
contained micronutrients (IFS and MMS) were more effective for reducing the prevalence of anemia. In general,
fortified foods were better accepted by the study participants than supplements.
ClinicalTrial.gov Identifier: NCT00822380.
Background
Micronutrient deficiencies continue to be a major public
health problem in many regions of the world. There
have been an increasing number of epidemiological stu-
dies demonstrating the high prevalence of micronutrient
deficiencies in different countries [1-3]. Other studies
have focused on the functional and health consequences
of micronutrient deficiencies [4,5]. However, more
longitudinal studies are needed to address important
issues on how to treat and prevent such deficiencies.
Among the consequences of micronutrient deficiencies
in different populations around the world, anemia is
perhaps the single best identified syndrome suffered by
a high proportion of the population. Anemia is present
in about 25% of the world’s population [6]. It has been
estimated that about 245 million children from 0 to 59
months of age are anemic in the world [7], and that
approximately 50% of the anemia is attributable to iron
deficiency [8,9]. Iron deficiency anemia (IDA) is present
in developing and in developed countries as well [10]. It
is known that other micronutrients deficiencies can
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any medium, provided the original work is properly cited.contribute to anemia in addition to iron [11]. In a pre-
vious study in low income populations in Mexico, about
30% of anemic subjects did not respond to iron supple-
mentation alone [12], suggesting that other nutrient
deficiencies might also be involved.
Several alternatives are available for prevention and/or
treatment of anemia. Iron supplementation with differ-
ent iron sources, particularly ferrous sulfate, has been
recommended and used in many regions of the world
for several years [9,13]. More recently, the addition of
other micronutrients to iron has been suggested. The
United Nations Children’s Fund (UNICEF) recommends
the utilization of an iron and folic acid supplement [14].
The use of complementary foods as a safer form to deli-
ver iron and other micronutrients has also been
explored in different countries [15]. In Mexico, a milk-
based powdered supplement that contains iron, zinc,
copper and several vitamins was developed to treat and
prevent micronutrient deficiencies and anemia in low-
income populations [16,17]. Iron fortification of foods
and beverages is another alternative to treat and prevent
anemia and today it is a common practice to add micro-
nutrients to different foods such as cereals, dairy foods,
snacks and beverages [16,18-21].
It is believed that an iron supplement or an iron forti-
fied food with added micronutrients will have a benefi-
cial effect on hemoglobin (Hb) status in children at risk
of micronutrient deficiencies. However, despite all the
different strategies developed to treat and prevent ane-
mia it is still not clear which strategy is more effective
in children in terms of adherence and efficacy. The
objective of the present study was to evaluate the effi-
cacy and children’s acceptance of several strategies that
have recently been recommended to treat anemia.
Methods
Subjects and place of the study
The study was carried out in 4 rural communities within
50 kilometers of the city of Queretaro in Mexico: La
Fuente, Los Cerritos, El Tejocote and Fuentezuelas. A
census of all families in these communities was done
before the study began; 2 months later, mothers of 577
children aged 6 to 42 mo were invited to participate.
Study details and potential risks and benefits were
explained to the mother or caretaker of each child, and
they voluntarily signed informed consent forms allowing
their children to participate. Hemoglobin concentration
was measured in all children from a capillary blood
sample after an overnight fast, and only those with ane-
mia (Hb < 11.7 g/dL) were included in the efficacy
study. Exclusion criteria also included exclusive breast-
feeding or consumption of industrialized formula,
chronic gastroenteritis or any other severe illness. Sib-
lings from an anemic child were included in the study
regardless of their anemia status but only anemic chil-
dren were included in the statistical analyses. Parents of
eligible children agreed not to give any other nutritional
supplement to their children while they were enrolled in
the study. Clinical evaluations and blood sample collec-
tions were done at the health clinics in the communities
which depend on the Ministry of Health. The study pro-
tocol was reviewed and approved by the Bioethics Com-
mittee of the University of Queretaro.
A sample size of 53 children per treatment group was
calculated to detect a difference of 0.6 g/dL in Hb
change with a standard deviation of 1.0 g/dL, an alpha
error of 0.05, a statistical power of 80% and a drop out
rate of 20%.
Experimental treatments and design
Anemic subjects were randomized into 1 of 5 treatment
groups. Ten groups of children, who entered the study
one at a time, were randomized independently to ensure
treatment balance within each group. Randomization
procedures also ensured homogeneous groups according
to Hb status, age and gender. Siblings were allocated to
the same treatment to facilitate treatment administration
by the mother. The randomization process was done
using a program specifically developed for the purpose
of this study in SAS version 8.1 (SAS Institute Inc. Cary,
NC) by personnel who were not in contact with the
subjects or fieldworkers.
Anemic children received one of the following treat-
ments: Iron supplement (IS), iron plus folic acid supple-
ment (IFS), a multiple micronutrients supplement
(MMS), a micronutrient fortified complementary food
as porridge powder (FCF), or water fortified with zinc,
iron and ascorbic acid (FW). Treatment IS is a standard
ferrous sulfate supplement made in liquid solution; IFS
is a liquid solution that follows the daily iron and folic
acid recommendation of UNICEF to treat anemia [14];
MMS is a supplement with multiple micronutrients spe-
cifically designed to treat anemia in low income popula-
tions in Mexico [22,23]. The FCF treatment consists of
a milk-based complementary food supplement designed
for the Oportunidades national program (formerly called
Progresa) in Mexico [16] which currently delivers about
five million doses every day. The food supplement is
prepared by dissolving the pre-measured powder in 25
mL of boiled water until forming porridge, and it is
eaten with a spoon. Lastly, FW treatment is drinking
water fortified with iron, zinc and ascorbic acid devel-
oped by Procter and Gamble (Cincinnati, OH); mothers
were asked to use this water for drinking and cooking
for the child. The nutrient composition and chemical
form of each treatment is described in Table 1.
All study personnel and participants were blinded to
the assignment of supplement treatments but not to
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to include these in the blinding scheme. The IS, IFS and
MMS treatments were provided in white plastic bottles
coded with different letters. All treatments were deliv-
ered once a week by field workers and were adminis-
tered daily to children at home during 4 months.
Mothers or caregivers were responsible for the prepara-
tion and administration of the treatments. On the first
day of the study, fieldworkers explained how to prepare
the treatments, and how and when to give them to the
children. The fieldworkers visited the participants twice
a week at their homes for the duration of the study, and
evaluated treatment administration, morbidity, and
treatment adherence and acceptance. The presence of
any adverse events was recorded by mothers and
reported every time the fieldworker visited the child.
Anthropometry evaluation
All children were weighed and measured at baseline and
after four months of receiving the treatment. Children
were weighed with an electronic scale (SECA erecta 844,
Hamburg, Germany) with no shoes or sweaters to the
nearest 100 g. Height was measured with a stadiometer
( S E C A2 1 6 ,H a m b u r g ,G e r m a n y )w i t hn os h o e s .
Younger children who could not stand still by them-
selves were weighed with a pediatric scale (SECA 334,
Hamburg, Germany) and their supine length was mea-
sured within 1 mm using a rigid measuring mat for
infants (SECA 210, Hamburg, Germany). Knee height
was measured using a Knemometer to the nearest 1
mm. The personnel who measured the children were
trained and standardized using calibrated methods and
standardized techniques according to the Official
Mexican Norm for children’s health care (NOM-031-
SSA2-1999). Each child was examined by the same per-
son at baseline and after intervention following the
same procedures.
Biochemical measurements
Hemoglobin concentration was measured with a photo-
meter (HemoCue Blood-Hemoglobin System, Ängel-
holm, Sweden) which was calibrated each time before
being used. According to the region altitude of 1600 m
and children’s age, anemia was defined when Hb < 11.7
g/dL [24,25].
A blood sample (7 mL) was collected from each ane-
mic child after an overnight fast at baseline and after 4
months of treatment to measure iron, ferritin concentra-
tions, and C reactive protein. Blood samples were col-
lected in mineral-free no-additives Vacutainer tubes
(Becton Dickinson, Franklin Lakes, NJ) and transported
to the laboratory in frozen gel within two hours. Sam-
ples were centrifuged at 1500 rpm for 15 min (Beckman
Allegra 21R, Palo Alto CA), plasma was separated and
aliquotted into 5 mL Eppendorf tubes previously labeled
and stored at -70°C until analysis.
Total iron was determined using an atomic absorption
spectrophotometer (Perkin Elmer, Mod. Analyst700).
Ferritin was determined by immunoradiometric assay
(Coat-A-Count Ferritin IRMA; Diagnostic Products).
Both analyses were done in triplicate, and the mean
value was used for data analysis. Ten samples that had
coefficient of variation > 25% were re-analyzed. Low fer-
ritin was defined as serum ferritin < 7 μg/L, and iron
deficiency was defined as total iron < 50 μg/dL [25].
The inflammation marker, C-reactive protein (CRP), was
measured with a qualitative method described by
Ortega-Heredia& Rodríguez-Sánchez [26] and was used
to exclude potential false positive values of ferritin and
total iron due to inflammation.
Morbidity evaluation
Morbidity was recorded by using a questionnaire which
evaluated general symptoms of upper and lower respira-
tory tract infections and gastrointestinal infections in
the previous 3 or 4 days. This questionnaire has been
validated and used in previous studies [27]. Morbidity
data was computed as frequency of diarrhea and respira-
tory infection episodes during the trial period. A diar-
rhea episode was defined as starting with at least 3
liquid bowel movements per day, and ending the day
before the subject did not experience the symptom for 7
consecutive days. The respiratory infection episode was
defined as starting when a subject experienced cough,
difficulty breathing, ear pain or fever along with a cold,
flu or sore throat and ending the day before the subject
did not experience any of the previous symptoms.
Table 1 Nutrient content of experimental treatments
Nutrient Daily dose by treatment
IS IFS MMS FCF FW*
Iron † (mg) 20 12.5 10 10 6.7
Zinc (mg) 10 10 5.6
Thiamine (mg) 0.6
Riboflavin (mg) 0.55 0.8
Pyridoxine (mg) 0.74
Vitamin B12 (μg) 0.55 0.7
Folic Acid (μg) 50 37.5 50
Vitamin C (mg) 30 40 44.4
Vitamin A (UI) 1349
Vitamin E (mg) 6
Iron supplement (IS), iron plus folic acid supplement (IFS), multiple
micronutrients supplement (MMS), micronutrient fortified complementary
food as porridge powder (FCF), or zinc, iron and ascorbic acid fortified water
(FW).
*Intake depended on the amount of water used for cooking in each family in
addition to drinking water, thus the value represents the average daily intake
in the children studied (0.89 L/d).
† FCF form of iron is reduced iron; all other treatments have ferrous sulfate.
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Once a week, a questionnaire was administered to the
mothers or caregivers to evaluate adherence to treat-
ments and the children’s acceptance of the different
treatments. During that visit, treatments were weighed
at the participants’ homes with an electronic scale
(Ohaus CS2000, Pine Brook, NJ, USA) to the nearest
1 g, except for the FW treatment, which was counted as
whole or 1/4, 1/2 or 3/4 fractions of bottles to record
and ensure its consumption. However, since the FW
was also used for cooking foods that some times were
also eaten by other family members, children’sa d h e r -
ence to the FW treatment was not possible to evaluate.
For the rest of the experimental groups, treatment
adherence was computed as the proportion of assigned
treatment that was consumed. An adherence value of
80% was considered adequate. The proportion of chil-
dren that completed 4 months of treatment was also
evaluated, regardless of the adherence to their assigned
treatment.
To assess acceptability of the treatments, mothers or
caregivers answered the following questions: 1) Does
your child like to take the treatment? 2) Has your child
had any difficulty taking the treatment? Each question
was computed as the number of times that the mother
reported her child having any difficulty taking the sup-
plement or disliked the treatment. These two outcome
variables were used to assess the children’s acceptance
of the treatments.
Data analysis
Of the 266 children enrolled in the study, 217 had com-
plete data sets. Statistical analyses were performed with
a data set that excluded subjects who did not complete
t h e1 7w e e k so fs t u d yo rd i dn o tt a k et h et r e a t m e n t
(Figure 1). Children (n = 48) that were lost to follow-up
did not participate in the final evaluation; thus an inten-
tion-to-treat analysis was not possible. Height-for-age,
weight-for-age and weight-for-height Z-scores were
computed using the WHO child growth standards using
the SPSS program provided by WHO [28]. Analyses
were performed using SPSS v.10.0 (Chicago, Ill).
To evaluate the effect of treatments on biochemical
variables and anthropometry, a univariate analysis of
variance was performed with the changes (final - base-
line) as the dependent variable, and gender and treat-
ment as fixed effects. Covariates were baseline values,
consumed iron (from the treatment formula multiplied
by the individual adherence to the treatment) and age;
community was included as a random effect. Differences
among treatments were tested by using the Least Signifi-
cant Difference test. Cases with a positive CRP (n = 15)
were removed from the data sets for ferritin and total
iron.
The effect of treatment on morbidity and child accept-
ability of the treatment was determined with the gener-
alized linear model procedure with the number of
episodes as the dependent variable, assuming the Pois-
son distribution with the log link function; the model
included the variables of age, community, gender and
baseline Hb. The Least Significant Difference test was
used to compare treatments.
Anemia prevalence at the end of the study, including
children that completed the study and that had adher-
ence to the treatment > 80% were compared with an
unadjusted chi-square test and with a model assuming
the binomial distribution and logit link function
adjusted for age and community, gender and baseline
Hb.
Analyses were performed in all children and stratified
into two groups by gender and by age using a cutoff
point of 24 months. Interactions among independent
variables were tested and were not significant.
Results
A total of 267 children out of the initial 577 sample
were anemic. One child had Hb ≤ 7 g/dL (6.0 g/dL),
was not included in the study and was referred to the
health clinic for further treatment. The flow of partici-
p a n t si ss h o w ni nFigure 1. Baseline characteristics of
266 subjects are presented in Table 2; these characteris-
tics were not significantly different among treatment
groups. Table 3 shows the effect of treatments on Hb,
ferritin and total iron. After 4 months, all treatments
increased Hb concentration (p < 0.05). Changes in Hb
concentrations with treatments MMS, IS and IFS were
significantly greater than FCF. In adjusted analysis, only
supplements with micronutrients (IFS and MMS)
increased Hb more than FCF (p < 0.05). Decrease in
prevalence of anemia in each treatment group was as
follows: MMS -26/36 (72%); IFS -29/42 (69%); IS -23/40
(58%); FW -25/48 (52%) and FCF -23/51 (45%). A Chi
square test showed a lower post-treatment prevalence of
anemia in subjects treated with MMS and IFS compared
with those treated with FCF (p < 0.05) (Figure 2). Sub-
group analyses in Hb response showed similar treatment
effects than the analyses that included all children.
All treatments were effective in increasing total iron
concentration; no significant differences were observed
in total iron concentrations among treatments at the
end of the study. The IS supplement significantly
increased ferritin concentration compared to its baseline
value. Unadjusted change in ferritin concentration in
the IS treatment group was significantly higher than
c h a n g e so b s e r v e di nI F Sa n dF W( p<0 . 0 5 ) ;h o w e v e r ,
when adjusting for the amount of consumed Fe and
other demographic confounders, the differences were no
longer significant.
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groups in weight-for-age, weight-for-height and height-
for-age changes (Table 4). Similarly, there were no sig-
nificant effects of treatment on the frequency of gastro-
intestinal and respiratory infection episodes. The mean
diarrhea episodes (95%CI) for IS, IFS, MMS, FW and
FCF were: 1.60 (1.21, 1.99), 1.90 (1.45, 2.35), 1.26 (0.87,
1.65), 1.82 (1.42, 2.22) and 1.90 (1.50, 2.31), respectively.
The mean respiratory infection episodes (95%CI) for IS,
IFS, MMS, FW and FCF were: 1.32 (0.97, 1.67), 1.84
(1.40, 2.27), 1.54 (1.12, 1.96), 1.66 (1.28, 2.03) and 1.69
(1.31, 2.06), respectively.
No differences were observed among groups in the
proportion of children that had an adherence > 80% or
in the children that completed the study (Table 5). The
MMS treatment had the lowest acceptability, followed
by, IFS and FCF; FW treatment had the fewest reported
intake difficulties (p < 0.05).
The proportion of children experiencing any adverse
event was: IS (4.3%), MMS (10.9%), FCF (5.4%), FW
(7.0%), IFS (4.9%). Most of the adverse effects were
related to allergies, infections and viral diseases, such as
chicken pox. All adverse events were diagnosed by the
physician of the health clinic and none of them was
related to the allocated treatment.
Discussion
Supplements Vs Fortified foods
In the present study, anemic children who received sup-
plements (MMS, IS, and IFS) to treat anemia, had a
Figure 1 Flowchart of participants.
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experimental group
Characteristics IS IFS MMS FW FCF
N 4 04 23 64 85 1
Age (m) 20.3 ±
9.4
20.8 ±
8.9
23.6 ±
9.1
22.4 ±
9.5
21.8 ±
8.9
Boys 42.5 47.6 47.2 52.1 52.9
Ferritin < 7 μg/L 50 31.6 56.3 30.4 44.9
Iron < 50 μg/dL 14.3 11.4 3.3 6.7 16.7
Height for age <
-2SD
32.5 19 20 27.1 17.6
Weight for height <
-2SD
2.5 7.1 0 4.2 0
Weight for age <
-2SD
2.5 0 0 0 0
Values are % or mean ± SD. There were no significant differences among
treatments with Chi square or ANOVA.
Treatment abbreviations: Iron supplement (IS), iron plus folic acid supplement
(IFS), multiple micronutrients supplement (MMS), micronutrient fortified
complementary food as porridge powder (FCF), or zinc, iron and ascorbic acid
fortified water (FW).
There are no significant differences among treatment groups with ANOVA or
Chi Square tests.
Table 3 Treatment effect in hemoglobin, ferritin and total iron concentrations of children
Evaluation IS IFS MMS FW FCF p
Hemoglobin
(g/dL)
N 4 04 23 64 85 1
Baseline 10.45 (10.18, 10.72) 10.72 (10.49, 10.95) 10.73 (10.52, 10.94) 10.55 (10.32, 10.78) 10.51 (10.22, 10.80) 0.487
Final 11.94 (11.60, 12.27)
1 12.24 (11.90, 12.58)
1 12.14 (11.80, 12.48)
1 11.62 (11.28, 11.96) 11.38 (11.07, 11.68)
2 0.001
Change 1.49 (1.13, 1.84)†
1 1.52 (1.13, 1.91)†
1 1.41 (1.05, 1.76)†
1 1.07 (0.77, 1.36)† 0.86 (0.60, 1.13)†
2 0.012
Adjusted change * 1.43 (1.05, 1.80) 1.58 (1.26, 1.89)
1 1.46 (1.08, 1.83)
1 1.25 (0.89, 1.62) 0.94 (0.65, 1.22)
2 0.034
Ferritin
(μg/dL)
N‡ 29 32 23 38 46
Baseline 30.04 (9.90, 50.18) 72.18 (41.64, 102.71) 22.83 (2.97, 42.69) 60.93 (36.55, 85.31) 57.95 (31.18, 84.72) 0.073
Final 55.50 (26.79, 84.22) 51.24 (26.83, 75.64) 20.53 (4.12, 36.94) 48.16 (21.33, 74.98) 60.45 (32.26, 88.63) 0.366
Change 25.47 (3.97, 46.96)†
1 -20.94 (-44.78, 2.89)
2 -2.30 (-10.61, 6.01) -12.77 (-35.49, 9.95)
2 2.49 (-17.90, 22.89) 0.042
Adjusted change * 21.43 (-4.05, 46.91) 0.94 (-19.50, 21.38) 0.67 (-24.96, 26.30) -4.06 (-26.80, 18.69) 20.29 (2.97, 37.62) 0.200
Total Iron
(μg/dL)
N‡ 26 30 21 33 46
Baseline 1.05 (0.90, 1.20) 1.01 (0.86, 1.16) 1.04 (0.88, 1.19) 1.17 (0.99, 1.34) 1.04 (0.90, 1.17) 0.822
Final 1.26 (1.08, 1.45) 1.16 (1.03, 1.29) 1.26 (1.02, 1.50) 1.35 (1.17, 1.53) 1.23 (1.09, 1.38) 0.604
Change 0.21 (0.08, 0.35)† 0.15 (0.04, 0.26)† 0.23 (0.04, 0.42)† 0.19 (0.06, 0.31)† 0.20 (0.10, 0.29)† 0.932
Adjusted change * 0.16 (0.00, 0.31) 0.13 (0.01, 0.25) 0.16 (0.00, 0.32) 0.25 (0.11, 0.39) 0.16 (0.05, 0.26) 0.771
Treatment abbreviations: Iron supplement (IS), iron plus folic acid supplement (IFS), multiple micronutrients supplement (MMS), micronutrient fortified
complementary food as porridge powder (FCF), or zinc, iron and ascorbic acid fortified water (FW).
Values are means (95% CI).
* Estimated changes adjusted for initial value, consumed iron in the treatment (according to formula and adherence to the treatment) and community.
† Change is significant within treatment at p < 0.05 in paired T-Test.
‡ Excludes children with positive C-Reactive Protein from qualitative analysis.
1,2 Different numbers indicate significant difference in the Least Significant Test at p < 0.05.
Figure 2 Post-treatment anemia prevalence of the initially
anemic children by treatment. Treatment abbreviations: Iron
supplement (IS), iron plus folic acid supplement (IFS), multiple
micronutrients supplement (MMS), micronutrient fortified
complementary food as porridge powder (FCF), or zinc, iron and
ascorbic acid fortified water (FW)
a, b Different letters represent
significant differences among treatments in a Chi Square test
(p < 0.05).
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received a fortified complementary food (FCF). When
adjusting for the amount of iron consumed, the change
in Hb concentration in only the IS group did not differ
from that of the FCF group. These results suggest that
other factors are more relevant than the amount of iron
given to treat anemia, and that the supplements increase
Hb concentrations of anemic children more than forti-
fied complementary foods.
Various studies have evaluated the effect of iron sup-
plements or fortified foods on anemia, but few studies
have evaluated both in the same trial. Ahmed et al.
compared the effect of iron in powder added to foods,
and iron in the form of syrup, in children with IDA and
found that both groups increased Hb concentration
similarly [29]. Thi Le et al. found that the effect of iron
fortified noodles on Hb concentration was about half of
the maximum impact of iron supplementation [30].
Similar to other trials [18,30,31], this study found that
FW and FCF increased Hb concentration and decreased
anemia prevalence, but the effect was greater when sup-
plements were used.
Table 4 Treatment effect in anthropometry measurements of children
Measurement IS IFS MMS FW FCF P
N 4 04 13 64 85 1
Height,
cm
Baseline 78.76 (76.26, 81.27) 79.84 (77.25, 82.44) 82.93 (80.34, 85.52) 80.49 (78.07, 82.91) 80.69 (78.58, 82.79) 0.260
Final 82.31 (80.02, 84.60) 83.63 (81.21, 86.06) 86.44 (84.04, 88.85) 83.97 (81.63, 86.30) 84.37 (82.39, 86.35) 0.219
Change 3.55 (3.06, 4.04)† 3.79 (3.33, 4.25)† 3.51 (3.05, 3.98)† 3.48 (3.11, 3.85)† 3.69 (3.30, 4.07)† 0.822
Adjusted change * 3.55 (3.21, 3.90) 3.67 (3.31, 4.03) 3.68 (3.30, 4.06) 3.71 (3.39, 4.04) 3.70 (3.38, 4.02) 0.971
Weight,
Kg
Baseline 10.50 (9.81, 11.18) 10.65 (9.97, 11.33) 11.44 (10.75, 12.13) 10.88 (10.24, 11.53) 11.04 (10.49, 11.58) 0.356
Final 11.19 (10.56, 11.81) 11.47 (10.75, 12.20) 12.22 (11.52, 12.92) 11.55 (10.87, 12.23) 11.68 (11.12, 12.25) 0.351
Change 0.69 (0.49, 0.90)† 0.82 (0.63, 1.02)† 0.78 (0.60, 0.96)† 0.67 (0.50, 0.83)† 0.65 (0.47, 0.82)† 0.603
Adjusted change * 0.73 (0.55, 0.90) 0.80 (0.62, 0.98) 0.81 (0.62, 1.00) 0.76 (0.60, 0.93) 0.68 (0.51, 0.84) 0.801
Knee height,
cm
Baseline 20.52 (19.65, 21.38) 20.65 (19.75, 21.55) 21.76 (20.85, 22.67) 21.03 (20.21, 21.84) 21.12 (20.41, 21.84) 0.332
Final 21.71 (20.89, 22.53) 22.10 (21.28, 22.93) 23.12 (22.25, 23.99) 22.21 (21.42, 22.99) 22.45 (21.76, 23.13) 0.213
Change 1.19 (0.99, 1.39)† 1.45 (1.26, 1.64)† 1.36 (1.12, 1.60)† 1.18 (1.01, 1.36)† 1.32 (1.13, 1.51)† 0.243
Adjusted change * 1.17 (0.99, 1.34) 1.30 (1.12, 1.49) 1.31 (1.12, 1.51) 1.11 (0.94, 1.27) 1.18 (1.02, 1.34) 0.383
Weight for age,
Z score
Baseline -0.41 (-0.76, -0.06) -0.40 (-0.70, -0.10) -0.32 (-0.63, -0.01) -0.42 (-0.74, -0.11) -0.24 (-0.50, 0.02) 0.898
Final -0.46 (-0.74, -0.17) -0.39 (-0.68, -0.09) -0.34 (-0.66, -0.02) -0.51 (-0.84, -0.19) -0.36 (-0.62, -0.10) 0.749
Change -0.05 (-0.23, 0.13) 0.01 (-0.14, 0.17) -0.02 (-0.11, 0.08) -0.09 (-0.21, 0.04) -0.12 (-0.25, 0.01) 0.669
Adjusted change * -0.02 (-0.15, 0.11) -0.01 (-0.14, 0.12) 0.00 (-0.14, 0.14) -0.02 (-0.14, 0.10) -0.08 (-0.20, 0.04) 0.908
Weight for height,
Z score
Baseline 0.33 (-0.01, 0.68) 0.28 (-0.01, 0.58) 0.35 (0.05, 0.65) 0.35 (0.04, 0.65) 0.50 (0.25, 0.76) 0.865
Final 0.84 (0.53, 1.15) 0.75 (0.44, 1.07) 0.91 (0.55, 1.27) 0.80 (0.46, 1.14) 0.76 (0.45, 1.08) 0.970
Change 0.51 (0.21, 0.80)† 0.47 (0.19, 0.74)† 0.56 (0.36, 0.75)† 0.45 (0.24, 0.67)† 0.26 (0.03, 0.49)† 0.446
Adjusted change * 0.53 (0.29, 0.76) 0.39 (0.14, 0.64) 0.53 (0.27, 0.78) 0.50 (0.28, 0.72) 0.31 (0.09, 0.53) 0.594
Height for age,
Z score
Baseline -1.27 (-1.63, -0.91) -1.16 (-1.46, -0.86) -1.09 (-1.41, -0.78) -1.32 (-1.63, -1.01) -1.19 (-1.44, -0.94) 0.868
Final -2.10 (-2.44, -1.76) -1.83 (-2.24, -1.42) -1.82 (-2.22, -1.43) -2.11 (-2.46, -1.76) -1.80 (-2.13, -1.48) 0.425
Change -0.83 (-1.11, -0.55)† -0.67 (-0.96, -0.37)† -0.73 (-0.94, -0.52)† -0.79 (-1.01, -0.57)† -0.61 (-0.86, -0.36)† 0.717
Adjusted change * -0.81 (-1.06, -0.56) -0.60 (-0.86, -0.34) -0.65 (-0.92, -0.37) -0.74 (-0.98, -0.50) -0.60 (-0.83, -0.37) 0.710
Treatment abbreviations: Iron supplement (IS), iron plus folic acid supplement (IFS), multiple micronutrients supplement (MMS), micronutrient fortified
complementary food as porridge powder (FCF), or zinc, iron and ascorbic acid fortified water (FW). Values are means (95% CI).
* Estimated changes adjusted for initial value and community. Weight, height and knee height are also adjusted for age.
† Change is significant within treatment at p < 0.05 in paired T-Test.
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Although the iron dose used to treat the anemic chil-
dren is twice as large in the IS supplement than the
MMS, no differences were found in the change in Hb
concentration among IS, MMS and IFS.
A systematic review of several clinical trials concluded
that the addition of multiple micronutrients to iron sup-
plementation marginally improved Hb response com-
pared with iron supplementation alone [32]. In the
present study, the inclusion of the micronutrients that
are known to be involved in erythropoiesis (MMS), or
the inclusion of folic acid (IFS), increased Hb in a simi-
lar way to iron alone (IS). However, the MMS and IFS
treatments were more effective for reducing the preva-
lence of anemia in children. The prevalence of anemia
decreased more in the MMS (14%) and IFS (11%)
groups than in the IS group, suggesting that the children
included in the study might have had other micronutri-
ent deficiencies that could be contributing to the pre-
sence of anemia.
Effects on morbidity
Iron supplementation has been found to increase the
number of diarrhea episodes. Gera and Sachdev
reviewed several trials and found that iron supplementa-
tion increases the risk of developing diarrhea by 0.05
more episodes per year, which is considered a low risk
[33]. Similar to other studies [34,35], this study did not
find a difference in diarrhea episodes among treatments.
There is no evidence that iron supplementation has an
adverse effect on respiratory tract infections. It has been
reported that the inclusion of micronutrients can
decrease the number of acute respiratory infections [36].
In the present study, no differences were found in
respiratory tract infections among treatment groups;
however it cannot be concluded that iron supplementa-
tion alone or with micronut r i e n t sd o e sn o ta f f e c t
respiratory infections due to the lack of a control group
with no treatment.
Effect on growth
No differences were observed on height-for-age, weight-
for-age, weight-for-height or knee height among treat-
ments. These findings agree with those of Sachdev et al.
who examined the effect of iron supplementation on
growth of children in 25 trials [37]. They also did not
find that iron supplementation affects growth. Also, it is
likely that the period of observation in this study was
not long enough to find any differences in growth
among treatments.
Importance of adherence and child rejection
There were no significant differences in adherence rates
among treatments. However, the supplements were not
as well accepted as the fortified foods (FCF and FW).
Therefore, the supplements increased Hb concentrations
and were effective, but they were less accepted by the
children. Most cases of rejection of the supplements
were attributed to flavor, probably due to the high con-
centration of minerals in the solutions. Careful attention
n e e d st ob ep r o v i d e dt ot h es e n s o r yc h a r a c t e r i s t i c so f
supplements during their development to minimize
rejection and improve adherence to treatment.
Limitations of the study and implications
In order to compare the efficacy and adherence to dif-
ferent strategies for treating anemia that have been
developed in recent years, this study evaluated treat-
ments with different iron content. Results show that the
smaller doses, such as 10 mg per day, are as effective as
larger doses to increase Hb and to reduce the preva-
l e n c eo fa n e m i a .C h i l d r e nf r o m6t o4 2m o n t h so fa g e
were studied and, since all children were non-breastfed
or partially breastfed, our findings cannot be generalized
Table 5 Treatment acceptance and adherence
Outcome variables IS IFS MMS FW FCF P
Acceptance of the treatment:
Trouble taking the treatment † 3.7 (3.1, 4.2)
2 1.9 (1.5, 2.4)
3 6.4 (5.5, 7.2)
1 1.3 (1.0, 1.6)
4 2.3 (1.9, 2.8)
3 < 0.001
Child dislike of the treatment † 5.1 (4.4, 5.8)
2 3.1 (2.6, 3.7)
3 7.4 (6.5, 8.4)
1 2.0 (1.6, 2.3)
4 3.1 (2.6, 3.6)
3 < 0.001
Adherence to the treatment:
Completed 80% of treatment dose, % 91.5 (83.4, 99.7) 89.2 (79.1, 99.4) 84.6 (71.9, 97.2) * 89.1 (80.1, 98.0) 0.795
Completed 4 m of treatment, % 83.2 (72.8, 93.6) 84.9 (74.5, 95.2) 71.0 (57.7, 84.4) 86.3 (77.1, 95.5) 88.5 (80.0, 97.0) 0.168
Treatment abbreviations: Iron supplement (IS), iron plus folic acid supplement (IFS), multiple micronutrients supplement (MMS), micronutrient fortified
complementary food as porridge powder (FCF), or zinc, iron and ascorbic acid fortified water (FW).
Values are estimated means (95%C.I.) adjusted for age and baseline Hb. P value for the treatment main effect evaluated in a generalized linear model assuming
the poisson distribution and log link function for adherence and rejection to the treatment variables and the binomial distribution and logit link function for the
completion of the study variable. Models were adjusted for community, baseline Hb, age and gender.
* FW treatment does not have an adherence reference parameter, thus this treatment was not included in the model.
† Number of weekly visits that the mother reported difficulty to give the treatment to the child.
1-4Different numbers indicate significant difference in the Least Significant Test at p < 0.05.
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in Mexico, only about 10% of children are still exclu-
sively breastfed between 9 to 12 months [38]. Another
limitation of the present study is that treatments were
consumed for 4 months; some of the treatments may
have been more effective if they had been consumed for
longer periods of time.
Conclusions
After evaluating the efficacy of different strategies to
t r e a ta n e m i af o r4m o n t h si tc a nb ec o n c l u d e dt h a ti n
Mexican children living in rural areas where the preva-
lence of anemia is high: 1) All treatments evaluated
increased Hb and reduced the prevalence of anemia. 2)
The three supplements (iron, iron plus folic acid and
iron plus micronutrients) increased Hb concentrations
significantly more than fortified complementary food. 3)
The supplements that contained other micronutrients or
folic acid were more effective for reducing the preva-
lence of anemia than fortified complementary food. 4)
Supplements were in general less accepted by children
than the food fortification strategies. This study demon-
strates that it is more important to consider other
micronutrients than to provide high doses of iron alone.
We suggest that attention should be given to other
micronutrient deficiencies to increase the effectiveness
of iron intervention programs.
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